Cyclerion Therapeutics (CYCN) Net Income (2018 - 2025)

Cyclerion Therapeutics (CYCN) posted quarterly Net Income of -$1.0 million for Q3 2025, up 39.83% quarter-over-quarter from -$1.7 million in Q2 2025.

Cyclerion Therapeutics (CYCN) Net Income (2018 - 2025) Analysis & Trends

Cyclerion Therapeutics' Net Income history runs 7 years deep, the most recent figure standing at -$1.0 million for Q3 2025.

In Q3 2025, Net Income changed N/A year-over-year to -$1.0 million; the TTM figure through Dec 2025 stood at -$4.1 million (changed N/A YoY), while the FY2023 annual figure was $7.3 million, up 128.38% from the prior year.
Net Income for Q3 2025 stood at -$1.0 million, up from -$1.7 million in the prior quarter.
The five-year high for Net Income was $13.5 million in Q3 2023, with the low at -$18.5 million in Q2 2021.
The 4-year median for Net Income is -$4.9 million (2022), against an average of -$6.7 million.
The sharpest annual moves came in 2021 and 2023: Net Income advanced 5.84% in 2021, then soared 321.28% in 2023.
Cyclerion Therapeutics' Net Income stood at -$15.7 million in 2021, then soared by 81.6% to -$2.9 million in 2022, then jumped by 565.74% to $13.5 million in 2023, then sank by 107.47% to -$1.0 million in 2025.
Business Quant data shows CYCN's Net Income at -$1.0 million in Q3 2025, -$1.7 million in Q2 2025, and -$1.5 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	1.10 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.30 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	482.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-782.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	237.01 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	164.49 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-355.03 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-13.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	81.49 Mn
10	Cyclerion Therapeutics	12.71 Mn	9.47 Mn	-	-

Download Data